Commentaries on Aduro-NVS deal: http://www.xconomy.com/san-francisco/2015/03/30/novartis-bets-250m-plus-on-aduros-immuno-oncology-work/ http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/03/aduro-biotech-novartis-nvs-sting-cdn-cancer.html